Quick Answer
VitaNova Life Sciences Corp reported Cash and Equivalents of $8.7 thousand for fiscal year 2023.
VitaNova Life Sciences Corp Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2023 | $8.7K | -62.2% |
| 2022 | $23.1K | — |
| 2021 | $0.00 | — |
| 2020 | $0.00 | — |
| 2019 | $0.00 | -100.0% |
| 2018 | $4.4K | +2056.6% |
| 2017 | $205.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| January 31, 2024 | $808.4K | +7240.0% | — |
| July 31, 2023 | $0.00 | -100.0% | -100.0% |
| April 30, 2023 | $8.7K | -62.2% | -20.7% |
| January 31, 2023 | $11.0K | -70.2% | -68.7% |
| October 31, 2022 | $35.2K | +11.0% | +17.8% |
| July 31, 2022 | $29.9K | — | +29.4% |
| April 30, 2022 | $23.1K | — | -37.4% |
| January 31, 2022 | $36.9K | — | +16.5% |
- VitaNova Life Sciences Corp showed a decrease of -62.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2017–2023 period, VitaNova Life Sciences Corp’s cash and equivalents has grown by 4157.6% (from $205.00 to $8.7 thousand).
- The most recent figure is from VitaNova Life Sciences Corp’s fiscal year 2023 report (Form 10-K), filed with the SEC on May 15, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: